AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria that represent a ...

Emblaveo is the second antibiotic approved for problem pathogens in the EU this year, raising hopes that after years of neglect due to the difficulty of getting a return on R&D investment for ...